CN116211857A - 用于治疗精神分裂症的伊潘立酮 - Google Patents

用于治疗精神分裂症的伊潘立酮 Download PDF

Info

Publication number
CN116211857A
CN116211857A CN202310398029.9A CN202310398029A CN116211857A CN 116211857 A CN116211857 A CN 116211857A CN 202310398029 A CN202310398029 A CN 202310398029A CN 116211857 A CN116211857 A CN 116211857A
Authority
CN
China
Prior art keywords
iloperidone
daily dose
pharmaceutically acceptable
acceptable salt
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310398029.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·波利梅洛伯罗斯
C·D·沃尔夫冈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CN116211857A publication Critical patent/CN116211857A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310398029.9A 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮 Pending CN116211857A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US62/117,173 2015-02-17
US201562172436P 2015-06-08 2015-06-08
US62/172,436 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia
CN201680010479.4A CN107249586A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680010479.4A Division CN107249586A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Publications (1)

Publication Number Publication Date
CN116211857A true CN116211857A (zh) 2023-06-06

Family

ID=55532275

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310398029.9A Pending CN116211857A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮
CN201680010479.4A Pending CN107249586A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680010479.4A Pending CN107249586A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Country Status (9)

Country Link
US (2) US10441580B2 (cg-RX-API-DMAC7.html)
EP (1) EP3258935B1 (cg-RX-API-DMAC7.html)
JP (1) JP6885649B2 (cg-RX-API-DMAC7.html)
KR (1) KR102870956B1 (cg-RX-API-DMAC7.html)
CN (2) CN116211857A (cg-RX-API-DMAC7.html)
BR (1) BR112017017608A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976383C (cg-RX-API-DMAC7.html)
ES (1) ES2870498T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016134049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
AU2023408198A1 (en) * 2022-12-19 2025-05-29 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
EP4687899A1 (en) 2023-06-02 2026-02-11 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone
WO2026156184A1 (en) 2025-01-17 2026-07-23 Vanda Pharmaceuticals Inc. Method of treatment with milsaperidone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132866A1 (en) * 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370634T3 (es) 2001-08-31 2011-12-21 Novartis Ag Isómeros ópticos de un metabolito de iloperidona.
CA2463158C (en) 2001-10-30 2013-07-30 Novartis Ag Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
WO2009036056A1 (en) * 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
WO2013080046A1 (en) * 2011-12-02 2013-06-06 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
KR20170008327A (ko) 2012-03-14 2017-01-23 반다 파마슈티칼즈, 인코퍼레이티드. 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132866A1 (en) * 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Also Published As

Publication number Publication date
BR112017017608A2 (en) 2018-05-08
WO2016134049A1 (en) 2016-08-25
US10987346B2 (en) 2021-04-27
EP3258935A1 (en) 2017-12-27
CA2976383A1 (en) 2016-08-25
CA2976383C (en) 2023-05-23
US20190388412A1 (en) 2019-12-26
EP3258935B1 (en) 2021-04-07
JP2018505901A (ja) 2018-03-01
US10441580B2 (en) 2019-10-15
KR102870956B1 (ko) 2025-10-16
JP6885649B2 (ja) 2021-06-16
HK1248551A1 (zh) 2018-10-19
CN107249586A (zh) 2017-10-13
US20180021324A1 (en) 2018-01-25
ES2870498T3 (es) 2021-10-27
KR20170118830A (ko) 2017-10-25

Similar Documents

Publication Publication Date Title
Bowden et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Quibell et al. Ketamine
Hermann et al. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
US10987346B2 (en) Iloperidone for the treatment of schizophrenia
Latorre et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICS
US20190091177A1 (en) Method of treating selected patient population experiencing dravet syndrome
NZ745778A (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
TW201919624A (zh) 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US10688075B2 (en) Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
AU2015332037A1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
Shiovitz et al. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder
US20230096920A1 (en) Treatment of demyelinating diseases
JP2015522077A5 (cg-RX-API-DMAC7.html)
HK1248551B (en) Iloperidone for the treatment of schizophrenia
Prantera et al. Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial
BR112020013820A2 (pt) inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia
JP2019001830A (ja) 医薬
Correll et al. The Effects of Valbenazine in Participants with Tardive Dyskinesia
CN108938645A (zh) 一种抗精神病药物组合物
JP2011528345A (ja) 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用
Detke et al. P. 3. a. 015 Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
JP2013537232A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination